Navigation Links
Scripps Research Institute receives $20 million to shed light on HIV drug resistance
Date:9/19/2012

LA JOLLA, CA, September 19, 2012 The Scripps Research Institute has received a grant totaling approximately $20 million over five years from the National Institutes of Health to research the development of drug resistance in HIV, the virus that causes AIDS.

The grant will create a new consortium, the HIV Interaction and Viral Evolution (HIVE) Center, to better understand drug resistance and lay the groundwork for developing new anti-HIV treatments.

"We're excited about the project," said Scripps Research Professor Arthur Olson, PhD, who is principal investigator of the new center. "Using HIV, we aim to develop a broad methodology to develop drugs in the context of the evolution of drug resistance. In the process, we'll pursue any new anti-HIV drug, combination, or approach we find that is robust in the face of drug resistance as a potential treatment regimen."

"This center brings together an impressive team of virologists and structural biologists to investigate the structure and function of HIV, including how it responds to the selective pressure imposed by the drugs used in AIDS therapy," said Michael Sakalian, PhD, the official who oversees the grant at the NIH National Institute of General Medical Sciences, which made the award with the National Institute of Allergy and Infectious Diseases. "Their efforts, which focus on elements of the virus that have been difficult to study, will further our understanding of host-pathogen interactions and ways to combat drug resistance."

The current effort grew out of Olson's 15 years of research on HIV protease, a viral enzyme that is a target for several anti-HIV drugs. While the laboratory had been making progress on this avenue of research, Olson realized that all three of the virus's enzymesprotease, integrase, and reverse transcriptasewere interacting as the virus mutated.

"A virus is a complex system, especially HIV, and there are all kinds of interplay between different drug targets," noted Olson. "There's a lot we don't know about how these enzymes interact with each other, other proteins, and human proteins."

To help fill in these gaps, Olson decided to propose a center to look at the evolution of resistance in the life cycle of the entire virus. He began reaching out to researchers with complementary specialties in the field of HIV research.

The result is a group of top researchers from across the country who will collaborate as part of the HIVE Center. The team includes: Edward Arnold, Ronald Levy, Roger Jones, and Joseph Marcotrigiano of Rutgers University; Alan N. Engelman of the Dana Farber Cancer Institute; Michael Parniak of the University of Pittsburgh; Mamuka Kvaratskhelia of Ohio State University; Alan Rein and Stephen Hughes of the National Cancer Institute-Frederick; and Richard K. Belew of Electronic Artifacts.

The group also includes scientists from both the Florida and California campuses of Scripps Research. On the California campus, joining the center will be David Goodsell, Bruce E. Torbett, Charles D. Stout, Vadim Cherezov, John Elder, and Valery V. Fokin. Contributing expertise from the Florida campus will be Patrick Griffin and Douglas Kotejin.

Olson notes the center will also draw on a clinical component that provides access to records and samples from active-duty military personnel receiving HIV treatment. This will enable the scientists to track changes in the evolution of the viral population under different conditions, including a change in treatment regimen.


'/>"/>
Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert  

Related medicine news :

1. Scripps Research scientists show how memory B cells stay in class to fight different infections
2. Scripps Florida scientists awarded nearly $1.5 million to develop new approaches to treat cancer
3. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
4. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
5. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
6. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
7. NIH awards $20 million over 5 years to train next generation of global health researchers
8. Researchers develop a new cell and animal model of inflammatory breast cancer
9. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
10. Sexually abused boys at risk for more unsafe sex: UBC research
11. Researchers Find Gene Mutations That May Be a Key to Autism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Research Institute receives $20 million to shed light on HIV drug resistance
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), ... solutions, today announced that its MyDario product is expected to appear on ... for when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: